NEXT Oncology, an Avacare business

02/04/2026

This World Cancer Day, we honor the patients and researchers driving progress in cancer care. Phase 1 clinical trials are a vital first step in translating promising science into hope.

02/03/2026

These preliminary results from Aprea Therapeutics are encouraging - congratulations! We are proud to be part of this trial.

“These early single-agent data demonstrate that APR-1051 has clinical activity as a single agent. The observation of a partial response on the first scan, together with a decrease in tumor marker at this dose level, supports continued clinical evaluation of APR-1051," commented NEXT Oncology's founder Anthony Tolcher.

Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patientThe unconfirmed partial response...

01/27/2026

Each year in the United States, about 13,000 new cases of cervical cancer are diagnosed and about 4,000 women die of this cancer. Be informed, and learn more here.

While NCCC is focused on cervical health and cervical cancer prevention all year long, Cervical Health Awareness Month in January is a time where we want to get as many people involved as we can. The World Health Organization has a plan for the elimination of cervical cancer through vaccination and....

01/21/2026

This Cervical Cancer Awareness Month, we recognize the importance of prevention, research, and continued progress in cancer care.

01/19/2026

01/13/2026

Did you know it’s cervical cancer awareness month? Learn more about cervical cancer here.

Learn about symptoms, risk factors, screening, and treatment.

12/05/2025

Thank you to the American Association for Cancer Research (AACR) for this fascinating roundtable on dose optimization featuring our own Anthony Tolcher.

Experts discussed challenges and opportunities for dose optimization of cancer treatments at the 2025 AACR-Industry Roundtable.

11/20/2025

Today on Day, we remember our friend and colleague Theresa Mays Hutchings.

11/12/2025

Congratulations to our colleagues at TOLREMO therapeutics!

“It is remarkable to see such rapid, deep and durable responses in NSCLC patients who had exhausted all prior treatments. TT125-802’s mechanism targeting non-oncogene addiction offers a novel approach to improving clinical outcomes for patients in this high-need setting.” Omar Saavedra Santa Gadea, NEXT Oncology, Barcelona

https://www.tolremo.com/press-releases/2025/20/8/tolremo-therapeutics-completes-first-in-human-dose-escalation-for-tt125-802-and-presents-solid-tumor-monotherapy-results-at-esmo-2025

11/05/2025

We are delighted to announce our expansion to Osaka, J*pan in collaboration with Dr. Toshio Shimizu and Kansai Medical University.

Read more:

With continued global expansion, NEXT Oncology is one of the world’s largest Phase I Cancer Trial organizations. [SAN ANTONIO, TX – November 5, 2025] NEXT Oncology, an Avacare business, has expanded its services to Asia through a strategic partnership with Kansai Medical University in Osaka, J*p...